Bis-benzylidine piperidone proteasome inhibitor with anticancer activity
US-9913834-B2 · Mar 13, 2018 · US
US12410141B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12410141-B2 |
| Application number | US-202117925923-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2021 |
| Priority date | May 18, 2020 |
| Publication date | Sep 9, 2025 |
| Grant date | Sep 9, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention of the instant application discloses spirocyclic guanidine compounds of general formula (I), shown below, and their use in methods of treating cancer
Opening claim text (preview).
The invention claimed is: 1. A compound selected from the group consisting of, 2. A method of treating cancer comprising administering a compound of claim 1 , wherein the cancer is selected from the group consisting of multiple myeloma, ovarian cancer, cervical cancer, breast cancer, liver cancer, and colon cancer. 3. The method of claim 2 , wherein the cancer is a liquid cancer or a solid cancer. 4. The method of claim 3 wherein the cancer is a solid cancer.
Antineoplastic agents · CPC title
Spiro-condensed · CPC title
containing carbocyclic rings other than six-membered · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Spiro-condensed ring systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.